Context Therapeutics Inc. SEC filings CNTX
Context Therapeutics Inc. has 307 filings in SEC EDGAR's recent list, going back to Mar 19, 2021. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 5, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 5, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Nov 14, 2024 | — |
| CORRESP | Letter to the SEC | Nov 12, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 12, 2024 | — |
| EFFECT | Filing | May 31, 2024 | — |
| CORRESP | Letter to the SEC | May 29, 2024 | — |
| UPLOAD | Letter from the SEC | May 29, 2024 | — |
| D | Filing | May 16, 2024 | — |
| EFFECT | Filing | Nov 16, 2022 | — |
| CORRESP | Letter to the SEC | Nov 14, 2022 | — |
| UPLOAD | Letter from the SEC | Nov 14, 2022 | — |
| EFFECT | Filing | Nov 10, 2022 | — |
| EFFECT | Filing | Apr 7, 2022 | — |
| EFFECT | Filing | Dec 16, 2021 | — |
| CORRESP | Letter to the SEC | Dec 14, 2021 | — |
| UPLOAD | Letter from the SEC | Dec 13, 2021 | — |
| SEC STAFF LETTER | Filing | Oct 20, 2021 | — |
| EFFECT | Filing | Oct 19, 2021 | — |
| CORRESP | Letter to the SEC | Oct 15, 2021 | — |
| CORRESP | Letter to the SEC | Oct 15, 2021 | — |
| CORRESP | Letter to the SEC | Sep 24, 2021 | — |
| UPLOAD | Letter from the SEC | Sep 22, 2021 | — |
| CORRESP | Letter to the SEC | Aug 2, 2021 | — |
| CORRESP | Letter to the SEC | Aug 2, 2021 | — |
| CERT | Filing | Jul 27, 2021 | — |
| 8-A12B | Filing | Jul 23, 2021 | — |
| CORRESP | Letter to the SEC | Jul 23, 2021 | — |
| CORRESP | Letter to the SEC | Jul 23, 2021 | — |
| CORRESP | Letter to the SEC | Jul 23, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 12, 2021 | — |
| CORRESP | Letter to the SEC | Jul 1, 2021 | — |
| CORRESP | Letter to the SEC | Jul 1, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 4, 2021 | — |
| SEC STAFF LETTER | Filing | May 27, 2021 | — |
| CORRESP | Letter to the SEC | May 27, 2021 | — |
| UPLOAD | Letter from the SEC | May 20, 2021 | — |
| DRS/A | Filing | May 3, 2021 | — |
| DRSLTR | Filing | Apr 30, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 22, 2021 | — |
| DRS | Filing | Mar 22, 2021 | — |
| DRSLTR | Filing | Mar 19, 2021 | — |
Showing 40 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CNTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Philadelphia, PA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1842952
- Former names
- Context Therapeutics LLC (until May 3, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.